Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study offers new insights into angiogenesis inhibitors

14.04.2003


In working to halt the overgrowth of blood vessels that feed cancerous tumors, the antiangiogenic molecules endostatin and tumstatin take two distinct and very different tactics, according to a study in the April 15 issue of the Proceedings of the National Academy of Sciences (PNAS).



These findings, which currently appear on-line, suggest for the first time that these two agents combined may prove more effective in battling cancer than either one used separately.

"Just as aspirin, acetaminophen and ibuprofen each work in different ways to relieve pain, it now appears that endogenous inhibitors like endostatin and tumstatin work in different ways to halt angiogenesis," explains the study’s senior author Raghu Kalluri, Ph.D., of the Center for Matrix Biology at Beth Israel Deaconess Medical Center (BIDMC). "These findings may help us to be more informed in the ways we use these molecules as potential drug candidates in the future."


Angiogenesis has been the focus of attention among cancer researchers for more than 30 years. The angiogenesis process takes place when a single layer of endothelial cells – which line the inside of the small blood vessels – break off from the vessels’ membrane and develop into new capillaries. In a number of diseases – including psoriasis, rheumatoid arthritis and diabetic retinopathy, as well as cancer – it is the unchecked growth of these capillaries that contributes to disease pathogenesis.

Over the years, scientists have identified a number of endogenous protein fragments which can put a halt to this process. Known as endogenous angiogenesis inhibitors, these include endostatin and tumstatin. Subsequent investigations have shown that these angiogenesis inhibitors might function by binding to a group of cell surface associated molecules known as integrins.

In this new study, Kalluri and his colleagues discovered that these two inhibitory molecules were binding to two separate and distinct integrins – endostatin to a5b1 integrin and tumstatin to aVb3 integrin – thereby achieving the same end effect of inhibiting angiogenesis, but by diverse mechanisms.

"While human endostatin targets the endothelial cells’ migratory abilities, human tumstatin prevents endothelial cells from proliferating," says Kalluri, who is an associate professor of medicine at Harvard Medical School. "These two different approaches lead to the same outcome – halting the outgrowth of the blood vessels and inhibition of tumor growth."

With this discovery, he adds, clinicians may be able to use these molecules in a more targeted fashion. "In order for endostatin to work, it has to be targeting tumors with the a5b1 positive tumor vasculature. Likewise, tumstatin must target tumors with aVb3 positive tumor vasculature," he explains. "Future clinical trials of these antiangiogenic therapies may benefit by building in these considerations."

"This is a very important piece of work," notes Judah Folkman, M.D., of Children’s Hospital Boston and Harvard Medical School, in whose laboratory endostatin was first discovered with Michael O’Reilly in 1997. "This paper shows an emerging set of proteins in the body which guard against abnormal angiogenesis, similar to the set of proteins that guard against blood clotting." This new finding, he adds, "suggests that because these two proteins inhibit angiogenesis by two separate pathways, they could eventually be used together for the treatment of cancer."

Study co-authors include Beth Israel Deaconess Medical Center researchers Akulapalli Sudhakar, Ph.D., Hikaru Sugimoto, M.D., Ph.D., Changqing Yang, M.D., Ph.D., Julie Lively, Ph.D., and Michael Zeisberg, M.D.


This study was funded by grants from the National Institutes of Health and funds from the Program in Matrix Biology at BIDMC. BIDMC owns patent rights to human tumstatin, which are exclusively licensed to Ilex Oncology, Inc. Raghu Kalluri and BIDMC hold equity in Ilex.

Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. Beth Israel Deaconess is the third largest recipient of National Institutes of Health research funding among independent U.S. teaching hospitals.

Bonnie Prescott | EurekAlert!
Further information:
http://www.bidmc.harvard.edu/

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>